-
1.发明授权Compounds having activity in correcting mutant-CFTR processing and uses thereof 有权具有校正突变体CFTR加工活性的化合物及其用途公开(公告)号：US08143295B2
公开(公告)日：2012-03-27
申请号：US11908591
申请日：2006-03-08
IPC分类号： A01N43/78
CPC分类号： A61K31/428 , A61K31/00 , A61K31/47 , A61K31/517 , A61K45/06
摘要： The invention provides compositions, pharmaceutical preparations and methods for correcting cellular processing (e.g., folding, trafficking, or post-translational modification) of a mutant-cystic fibrosis transmembrane conductance regulator protein (e.g., ΔF508 CFTR) that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more aminobenzothiazole-containing compounds, aminoarylthiazole-containing compounds, quinazolinylaminopyrimidinone-containing compounds, bisaminomethylbithiazole-containing compounds, or phenylaminoquino-line-containing compounds of the invention, or an analog or derivative thereof.
摘要翻译： 本发明提供用于校正可用于治疗的突变型囊性纤维化跨膜传导调节蛋白（例如，＆Dgr; F508CFTR）的细胞加工（例如折叠，贩运或翻译后修饰）的组合物，药物制剂和方法 的囊性纤维化（CF）。 本发明的组合物和药物制剂可以包含一种或多种含氨基苯并噻唑的化合物，含氨基芳基噻唑的化合物，含喹唑啉氨基嘧啶酮的化合物，含二氨基甲基联噻唑的化合物或本发明的含苯基氨基喹啉系的化合物或其类似物或衍生物 。
-
2.发明授权Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof 有权通过突变体CFTR增加离子迁移活性的化合物及其用途公开(公告)号：US07939558B2
公开(公告)日：2011-05-10
申请号：US11628411
申请日：2005-06-02
IPC分类号： A61K31/404 , C07D209/04
CPC分类号： A61K31/405
摘要： The invention provides compositions, pharmaceutical preparations and methods for increasing activity (e.g., ion transport) of the mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR), e.g., ΔF508 CFTR, G551D-CFTR, G1349D-CFTR, or D1152H-CFTR, that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more phenylglycine-containing compounds or sulfonamide-containing compounds of the invention, or an analog or derivative thereof.
摘要翻译： 本发明提供组合物，药物制剂和增加突变型囊性纤维化跨膜传导调节蛋白（突变体-CFTR）的活性（例如离子转运）的方法，例如＆Dgr; F508CFTR，G551D-CFTR，G1349D-CFTR或D1152H -CFTR，可用于治疗囊性纤维化（CF）。 本发明的组合物和药物制剂可以包含一种或多种本发明的含苯基甘氨酸的化合物或含磺酰胺的化合物或其类似物或衍生物。
-
3.发明申请Compounds Having Activity in Increasing Ion Transport by Mutant-CFTR and Uses Thereof 审中-公开具有增加离子转运活性的化合物通过突变体CFTR及其用途公开(公告)号：US20120101143A1
公开(公告)日：2012-04-26
申请号：US13088216
申请日：2011-04-15
IPC分类号： A61K31/405 , A61P43/00 , C12N5/071 , A61K31/357
CPC分类号： A61K31/405
摘要： The invention provides compositions, pharmaceutical preparations and methods for increasing activity (e.g., ion transport) of the mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR), e.g., DF508 CFTR, G551D-CFTR, G1349D-CFTR, or D1152H-CFTR, that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more phenylglycine-containing compounds or sulfonamide-containing compounds of the invention, or an analog or derivative thereof.
摘要翻译： 本发明提供组合物，药物制剂和增加突变型囊性纤维化跨膜传导调节蛋白（突变型CFTR）的活性（例如离子转运）的方法，例如DF508CFTR，G551D-CFTR，G1349D-CFTR或D1152H-CFTR ，可用于治疗囊性纤维化（CF）。 本发明的组合物和药物制剂可以包含一种或多种本发明的含苯基甘氨酸的化合物或含磺酰胺的化合物或其类似物或衍生物。
-
4.发明申请Compounds Having Activity in Increasing Ion Transport by Mutant-Cftr and Uses Thereof 有权具有增加离子转运活性的化合物及其用途公开(公告)号：US20080319008A1
公开(公告)日：2008-12-25
申请号：US11628411
申请日：2005-06-02
IPC分类号： A61K31/165 , A61K31/47 , C12N5/02
CPC分类号： A61K31/405
摘要： The invention provides compositions, pharmaceutical preparations and methods for increasing activity (e.g., ion transport) of the mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR), e.g., ΔF508 CFTR, G551D-CFTR, G1349D-CFTR, or D1152H-CFTR, that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more phenylglycine-containing compounds or sulfonamide-containing compounds of the invention, or an analog or derivative thereof.
摘要翻译： 本发明提供组合物，药物制剂和增加突变型囊性纤维化跨膜传导调节蛋白（突变体-CFTR）的活性（例如离子转运）的方法，例如DeltaF508CFTR，G551D-CFTR，G1349D-CFTR或D1152H-CFTR ，可用于治疗囊性纤维化（CF）。 本发明的组合物和药物制剂可以包含一种或多种本发明的含苯基甘氨酸的化合物或含磺酰胺的化合物或其类似物或衍生物。
-
5.发明申请Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof 有权具有纠正突变型CFTR加工活性的化合物及其用途公开(公告)号：US20080318984A1
公开(公告)日：2008-12-25
申请号：US11908591
申请日：2006-03-08
IPC分类号： A61K31/428 , C07D417/04 , C07D417/12 , A61K31/517 , A61P43/00 , A61K31/4439 , C07D403/12
CPC分类号： A61K31/428 , A61K31/00 , A61K31/47 , A61K31/517 , A61K45/06
摘要： The invention provides compositions, pharmaceutical preparations and methods for correcting cellular processing (e.g., folding, trafficking, or post-translational modification) of a mutant-cystic fibrosis transmembrane conductance regulator protein (e.g., ΔF508 CFTR) that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more aminobenzothiazole-containing compounds, aminoarylthiazole-containing compounds, quinazolinylaminopyrimidinone-containing compounds, bisaminomethylbithiazole-containing compounds, or phenylaminoquino-line-containing compounds of the invention, or an analog or derivative thereof.
摘要翻译： 本发明提供用于校正可用于治疗囊性的突变型囊性纤维化跨膜传导调节蛋白（例如，DeltaF508CFTR）的细胞加工（例如，折叠，贩运或翻译后修饰）的组合物，药物制剂和方法 纤维化（CF）。 本发明的组合物和药物制剂可以包含一种或多种含氨基苯并噻唑的化合物，含氨基芳基噻唑的化合物，含喹唑啉基氨基嘧啶酮的化合物，含二氨基甲基联噻唑的化合物或本发明的含苯基氨基喹啉系的化合物或其类似物或衍生物 。
-
-
-
-
搜索结果
5 条记录 (耗时 0.026 秒)
